BioCryst Pharmaceuticals (BCRX) Financials

$8.29 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$8.41 +0.13 (+1.51%)

As of 05/22/2026 07:55 PM Eastern

Annual Income Statements for BioCryst Pharmaceuticals

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-43	-55	-66	-101	-109	-183	-184	-247	-225	-89	263
Consolidated Net Income / (Loss)	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89	264
Net Income / (Loss) Continuing Operations	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89	264
Total Pre-Tax Income	-43	-55	-66	-101	-109	-183	-182	-244	-226	-87	267
Total Operating Income	-39	-49	-57	-94	-99	-175	-178	-148	-104	-2.54	341
Total Gross Profit	47	24	24	21	45	16	150	264	327	438	856
Total Revenue	48	26	25	21	49	18	157	271	331	451	875
Operating Revenue	48	26	25	21	49	18	157	271	331	451	875
Total Cost of Revenue	1.37	2.30	1.14	0.00	3.73	1.55	7.23	6.41	4.48	12	19
Operating Cost of Revenue	1.37	2.30	1.14	0.00	3.73	1.55	7.23	6.41	4.48	12	19
Total Operating Expenses	86	73	81	115	145	191	328	413	431	441	515
Selling, General & Admin Expense	13	11	14	30	37	68	119	159	214	266	349
Research & Development Expense	73	61	67	85	107	123	209	253	217	175	166
Total Other Income / (Expense), net	-3.58	-6.54	-8.37	-7.03	-9.44	-8.06	-4.09	-96	-123	-84	-74
Interest Expense	5.20	6.49	8.57	6.92	9.96	7.09	3.46	99	137	99	96
Interest & Investment Income	1.63	-0.05	0.19	-	0.52	-0.97	-0.63	3.14	15	14	11
Other Income / (Expense), net	-	-	-	-0.11	-	-	-	-	0.00	0.00	12
Income Tax Expense	-	-	-	-	0.00	0.00	2.25	2.73	0.31	1.93	3.53
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.08	-0.19	0.23	-	-0.34	0.04	-0.17	-0.89	-1.31	0.42	0.88
Basic Earnings per Share	($0.59)	($0.75)	($0.78)	($0.98)	($940.00)	($1.09)	($1.03)	($1.33)	($1.18)	($0.43)	$1.26
Weighted Average Basic Shares Outstanding	73M	73.30M	84.60M	103.40M	154.19M	167.27M	179.12M	185.91M	192.20M	206.70M	209.89M
Diluted Earnings per Share	($0.59)	($0.75)	($0.78)	($0.98)	($940.00)	($1.09)	($1.03)	($1.33)	($1.18)	($0.43)	$1.21
Weighted Average Diluted Shares Outstanding	72.90M	73.70M	84.45M	103.19M	115.60M	167.27M	179.12M	185.91M	192.20M	206.70M	218.58M
Weighted Average Basic & Diluted Shares Outstanding	73M	73.30M	84.60M	103.40M	154.19M	177.18M	184.66M	188.45M	206.15M	208.96M	250.80M

This table shows BioCryst Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-36	-61	-36	-13	-12	-28	0.24	5.60	12	245	-722
Consolidated Net Income / (Loss)	-36	-62	-35	-13	-14	-27	0.03	5.09	13	246	-722
Net Income / (Loss) Continuing Operations	-36	-62	-35	-13	-14	-27	0.03	5.09	13	246	-722
Total Pre-Tax Income	-36	-63	-35	-13	-13	-26	0.76	6.49	12	248	-721
Total Operating Income	-12	-43	-14	8.76	7.69	-4.51	21	30	30	260	-702
Total Gross Profit	86	92	91	108	114	125	141	161	157	397	151
Total Revenue	87	93	93	109	117	132	146	163	159	407	156
Operating Revenue	87	93	93	109	117	132	146	163	159	407	156
Total Cost of Revenue	1.10	1.56	1.27	1.70	3.21	6.09	4.57	2.80	2.19	9.52	5.38
Operating Cost of Revenue	1.10	1.56	1.27	1.70	3.21	6.09	4.57	2.80	2.19	9.52	5.38
Total Operating Expenses	98	135	106	99	106	130	120	131	128	137	853
Selling, General & Admin Expense	51	64	59	61	65	80	82	87	83	96	95
Research & Development Expense	47	70	46	38	41	49	37	43	45	41	758
Total Other Income / (Expense), net	-24	-20	-21	-21	-21	-21	-20	-23	-17	-12	-19
Interest Expense	27	25	25	25	25	24	23	26	22	25	20
Interest & Investment Income	3.45	4.09	3.73	3.47	3.69	2.97	3.03	2.45	2.27	2.77	2.03
Other Income / (Expense), net	-	-	-	-	0.00	-	0.00	-	2.67	-	-1.46
Income Tax Expense	0.33	-1.43	0.37	0.17	0.59	0.80	0.73	1.40	-0.77	2.17	1.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.11	0.59	0.31	0.21	-1.74	1.73	-0.21	-0.51	0.51	-	0.41
Basic Earnings per Share	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)	$0.00	$0.02	$0.06	$1.18	($2.98)
Weighted Average Basic Shares Outstanding	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M	208.88M	209.52M	210.18M	209.89M	242.26M
Diluted Earnings per Share	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)	$0.00	$0.02	$0.06	$1.13	($2.98)
Weighted Average Diluted Shares Outstanding	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M	215.26M	219.89M	219.89M	218.58M	242.26M
Weighted Average Basic & Diluted Shares Outstanding	204.81M	206.15M	206.38M	206.89M	207.13M	208.96M	209.25M	209.92M	210.54M	250.80M	254.16M

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	-26	-6.86	30	-25	87	159	233	-201	-194	-6.12	-15
Net Cash From Operating Activities	-13	-53	-41	-93	-90	-135	-142	-162	-95	-52	347
Net Cash From Continuing Operating Activities	-13	-53	-41	-93	-90	-135	-142	-162	-95	-52	347
Net Income / (Loss) Continuing Operations	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89	264
Consolidated Net Income / (Loss)	-43	-55	-66	-101	-109	-183	-184	-247	-227	-89	264
Depreciation Expense	0.18	0.48	0.70	0.77	0.72	0.75	0.78	1.44	1.66	1.25	1.39
Amortization Expense	1.01	1.08	1.03	1.00	1.40	3.45	54	97	5.18	0.17	-2.94
Non-Cash Adjustments To Reconcile Net Income	9.71	8.50	13	9.40	18	16	-21	46	157	46	142
Changes in Operating Assets and Liabilities, net	19	-8.36	10	-2.48	-0.53	28	8.12	-59	-32	-10	-57
Net Cash From Investing Activities	-18	23	-65	4.77	78	-6.86	16	-128	-131	53	-14
Net Cash From Continuing Investing Activities	-18	23	-65	4.77	78	-6.86	16	-128	-131	53	-14
Purchase of Property, Plant & Equipment	-5.12	-5.28	-0.33	-0.37	-0.34	-0.51	-2.39	-1.35	-2.17	-1.12	-2.47
Purchase of Investments	-54	-14	-108	-63	-3.02	-50	-10	-244	-514	-267	-262
Sale of Property, Plant & Equipment	-	-	0.01	-	-	-	-	-	0.00	0.00	0.55
Divestitures	-	-	-	-	-	-	-	-	0.00	0.00	-6.18
Sale and/or Maturity of Investments	42	43	43	68	81	43	28	117	385	320	257
Net Cash From Financing Activities	5.48	23	136	63	99	301	360	88	32	-5.76	-350
Net Cash From Continuing Financing Activities	5.48	23	136	63	99	301	360	88	32	-5.76	-350
Repayment of Debt	0.00	0.00	0.00	-4.03	0.00	-52	0.00	0.00	-273	0.00	-310
Issuance of Debt	-	23	0.00	10	19	120	0.00	73	300	0.00	0.00
Issuance of Common Equity	0.00	0.00	134	53	78	108	66	15	8.34	3.44	9.12
Other Financing Activities, net	5.48	0.65	1.70	2.78	1.24	125	294	0.19	-3.00	-9.21	-49
Effect of Exchange Rate Changes	-	-	-	-	0.00	-	0.07	0.57	0.36	-0.94	1.27
Cash Interest Paid	-	-	-	-	-	-	0.90	0.00	22	30	24

This table details how cash moves in and out of BioCryst Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	4.70	-40	-26	-5.93	19	7.26	0.56	-3.71	-2.28	-9.56	82
Net Cash From Operating Activities	-20	-8.92	-54	-1.37	8.25	-5.21	-28	41	42	292	-62
Net Cash From Continuing Operating Activities	-20	-8.92	-54	-1.37	8.25	-5.21	-28	41	42	292	-62
Net Income / (Loss) Continuing Operations	-36	-62	-35	-13	-14	-27	0.03	5.09	13	246	-722
Consolidated Net Income / (Loss)	-36	-62	-35	-13	-14	-27	0.03	5.09	13	246	-722
Depreciation Expense	0.42	0.42	0.31	0.32	0.31	0.31	0.33	0.33	0.34	0.39	0.46
Amortization Expense	20	16	16	16	12	11	-0.84	-14	-0.32	-1.09	0.85
Non-Cash Adjustments To Reconcile Net Income	12	18	14	13	19	21	35	11	12	98	721
Changes in Operating Assets and Liabilities, net	-16	18	-49	-18	-9.13	-11	-62	39	17	-51	-63
Net Cash From Investing Activities	23	-28	29	-2.45	8.49	18	27	29	14	-83	-269
Net Cash From Continuing Investing Activities	23	-28	29	-2.45	8.49	18	27	29	14	-83	-269
Purchase of Property, Plant & Equipment	-0.99	-0.55	-0.24	-0.16	-0.06	-0.68	-0.14	-0.18	-1.34	-0.80	-0.40
Acquisitions	-	-	-	-	-	-	0.00	-	-	-	-489
Purchase of Investments	-124	-157	-88	-112	-27	-40	-49	-29	-59	-126	0.00
Sale and/or Maturity of Investments	148	129	117	110	35	58	76	59	73	49	221
Net Cash From Financing Activities	1.23	-3.17	-1.05	-1.97	1.27	-4.02	0.53	-74	-59	-218	413
Net Cash From Continuing Financing Activities	1.23	-3.17	-1.05	-1.97	1.27	-4.02	0.53	-74	-59	-218	413
Repayment of Debt	-0.26	-	-	-	-	-	0.00	-	-48	-190	-4.95
Issuance of Debt	-	-	-	-	-	-	0.00	-	-	-	400
Issuance of Common Equity	1.48	0.04	1.68	0.26	2.09	-0.59	2.39	3.42	2.65	0.66	19
Other Financing Activities, net	0.01	-3.21	-2.73	-2.23	-0.81	-3.44	-1.86	-5.35	-14	-28	-2.01
Effect of Exchange Rate Changes	0.25	0.52	-0.34	-0.14	0.85	-1.30	0.45	-	-	-0.07	-0.07
Cash Interest Paid	4.85	4.99	4.99	5.05	10	10	9.15	7.53	6.11	0.95	6.08
Cash Income Taxes Paid	0.32	-0.01	0.19	0.68	0.36	0.38	0.00	1.23	0.99	-	1.43

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	122	90	178	147	175	335	588	550	517	490	514
Total Current Assets	64	67	125	114	164	324	566	517	496	422	404
Cash & Equivalents	29	22	50	27	114	272	504	305	111	105	90
Restricted Cash	1.61	1.55	3.29	1.54	1.55	2.22	3.35	1.47	1.80	0.21	0.20
Short-Term Investments	23	33	64	78	22	28	3.21	120	278	216	185
Accounts Receivable	6.24	8.77	6.12	4.29	22	8.65	29	51	57	79	107
Inventories, net	1.61	0.50	0.00	1.65	0.00	7.04	16	28	29	8.09	5.40
Prepaid Expenses	2.67	1.44	1.38	2.40	4.42	5.53	9.99	13	20	14	17
Plant, Property, & Equipment, net	5.15	9.92	9.55	-	7.35	7.11	8.71	8.62	7.91	7.78	8.78
Total Noncurrent Assets	53	13	43	-	3.59	3.80	13	25	13	61	101
Long-Term Investments	48	8.93	41	22	-	0.00	6.83	18	0.00	20	61
Other Noncurrent Operating Assets	5.73	4.01	2.03	0.98	3.59	3.80	6.47	6.81	13	40	40
Total Liabilities & Shareholders' Equity	122	90	178	147	175	335	588	550	517	490	514
Total Liabilities	75	88	94	-	137	354	695	845	972	966	633
Total Current Liabilities	62	54	75	69	92	106	104	106	150	160	196
Accounts Payable	9.31	4.27	6.34	7.77	14	19	28	14	21	12	16
Accrued Expenses	16	11	13	16	21	34	73	88	103	113	126
Current Deferred Revenue	2.16	2.02	8.48	0.22	2.12	0.15	1.42	1.22	-	-	0.00
Other Current Liabilities	-	-	-	-	1.38	1.18	1.82	2.37	26	35	54
Total Noncurrent Liabilities	12	34	20	-	45	248	591	739	823	806	437
Long-Term Debt	0.00	23	17	25	41	120	136	232	303	315	0.00
Capital Lease Obligations	2.38	2.70	2.75	-	3.41	-	-	-	-	2.12	1.44
Noncurrent Deferred Revenue	10	8.43	0.16	0.05	-	-	-	-	-	-	0.00
Other Noncurrent Operating Liabilities	-	-	-	2.70	0.00	129	455	507	519	489	436
Total Equity & Noncontrolling Interests	48	1.58	84	-	38	-19	-107	-295	-456	-476	-119
Total Preferred & Common Equity	48	1.58	84	-	38	-19	-107	-295	-456	-476	-119
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	48	1.58	84	-	38	-19	-107	-295	-456	-476	-119
Common Stock	559	568	716	782	879	1,004	1,100	1,160	1,224	1,293	1,387
Retained Earnings	-511	-566	-632	-732	-841	-1,023	-1,208	-1,455	-1,681	-1,770	-1,506
Accumulated Other Comprehensive Income / (Loss)	-0.21	-0.01	-0.24	-0.30	0.04	0.00	0.18	0.03	1.34	0.92	0.04

This table presents BioCryst Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	559	510	530	523	468	472	491	480	457	446	465
Total Current Assets	509	491	511	502	447	363	427	410	398	356	374
Cash & Equivalents	247	155	146	151	84	78	97	105	88	84	172
Restricted Cash	1.44	1.46	1.57	1.58	1.80	1.80	0.81	0.29	0.49	0.58	0.85
Short-Term Investments	180	243	264	247	252	194	233	190	172	129	67
Accounts Receivable	43	49	58	54	61	69	72	93	91	91	109
Inventories, net	27	27	27	30	30	4.45	7.56	6.87	5.04	5.23	5.99
Prepaid Expenses	11	15	14	20	18	16	16	14	13	17	19
Plant, Property, & Equipment, net	8.46	8.38	8.44	9.00	7.83	7.66	7.42	7.59	8.46	8.40	9.37
Total Noncurrent Assets	41	10	10	11	13	101	57	62	50	82	82
Long-Term Investments	34	3.43	3.45	0.00	-	64	19	21	10	40	21
Other Noncurrent Operating Assets	6.80	7.05	6.95	11	13	37	37	42	37	39	61
Total Liabilities & Shareholders' Equity	559	510	530	523	468	472	491	480	457	446	465
Total Liabilities	801	838	919	934	944	948	960	932	879	834	1,019
Total Current Liabilities	82	85	93	91	120	129	154	140	177	190	195
Accounts Payable	8.62	6.25	14	11	12	7.79	13	10	8.59	5.57	11
Accrued Expenses	69	75	75	77	79	90	104	93	107	119	119
Current Deferred Revenue	1.55	1.20	1.78	0.52	-	-	-	-	-	-	5.41
Other Current Liabilities	2.20	2.49	2.53	2.28	29	32	36	37	38	39	60
Total Noncurrent Liabilities	720	753	825	843	824	819	806	792	702	644	824
Long-Term Debt	224	233	293	298	308	314	314	315	243	194	395
Capital Lease Obligations	5.97	5.93	5.80	9.97	-	-	-	2.31	2.04	1.74	1.17
Noncurrent Deferred Revenue	-	-	-	-	-	-	-	-	-	-	8.83
Other Noncurrent Operating Liabilities	490	514	526	535	516	505	492	474	456	448	418
Total Equity & Noncontrolling Interests	-243	-328	-389	-411	-476	-476	-469	-452	-422	-388	-554
Total Preferred & Common Equity	-243	-328	-389	-411	-476	-476	-469	-452	-422	-388	-554
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-243	-328	-389	-411	-476	-476	-469	-452	-422	-388	-554
Common Stock	1,141	1,179	1,194	1,208	1,240	1,253	1,272	1,317	1,342	1,363	1,675
Retained Earnings	-1,383	-1,508	-1,583	-1,619	-1,717	-1,729	-1,743	-1,770	-1,765	-1,752	-2,228
Accumulated Other Comprehensive Income / (Loss)	-0.10	0.59	0.69	0.80	0.77	0.56	2.29	1.13	1.65	1.14	-0.37

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	254.62%	-45.39%	-4.43%	-18.00%	136.45%	-63.53%	782.38%	72.31%	22.37%	36.00%	94.10%
EBITDA Growth	15.00%	-22.97%	-18.35%	-66.26%	-5.16%	-75.23%	28.04%	59.38%	46.82%	306.82%	31,153.36%
EBIT Growth	13.82%	-23.23%	-18.11%	-64.30%	-5.44%	-75.71%	-1.70%	16.48%	30.13%	97.55%	13,984.35%
NOPAT Growth	13.82%	-23.23%	-18.11%	-64.11%	-5.56%	-75.71%	-1.70%	16.48%	30.13%	97.55%	19,002.72%
Net Income Growth	4.80%	-28.19%	-19.29%	-53.92%	-7.55%	-67.88%	-0.68%	-34.26%	8.33%	60.77%	396.87%
EPS Growth	13.24%	-27.12%	-4.00%	-25.64%	-95,818.37%	99.88%	5.50%	-29.13%	11.28%	63.56%	381.40%
Operating Cash Flow Growth	65.98%	-307.43%	23.01%	-124.98%	3.22%	-50.82%	-5.22%	-13.85%	41.22%	45.32%	767.76%
Free Cash Flow Firm Growth	63.47%	-258.63%	33.97%	-102.67%	-15.71%	134.99%	698.80%	-140.10%	57.62%	-16.73%	754.25%
Invested Capital Growth	-582.77%	94.88%	-911.33%	1.94%	83.66%	-11,085.43%	-224.82%	-3.71%	-7.15%	7.48%	9.01%
Revenue Q/Q Growth	-1.72%	19.94%	-16.82%	-5.32%	312.49%	-66.72%	37.83%	13.58%	4.36%	9.24%	45.85%
EBITDA Q/Q Growth	-5.73%	16.30%	-20.99%	-8.91%	20.71%	-42.04%	11.32%	38.49%	-677.54%	154.10%	171.88%
EBIT Q/Q Growth	-5.45%	15.63%	-20.26%	-8.65%	20.19%	-42.70%	0.13%	3.80%	3.39%	93.75%	363.99%
NOPAT Q/Q Growth	-5.45%	15.63%	-20.26%	-8.52%	20.19%	-42.70%	0.13%	3.80%	3.39%	93.75%	531.70%
Net Income Q/Q Growth	-17.68%	19.82%	-29.64%	-8.45%	18.56%	-46.32%	18.84%	-27.81%	4.15%	28.22%	3,105.59%
EPS Q/Q Growth	-15.69%	19.35%	-21.88%	-5.38%	-77,585.95%	99.92%	-100.21%	-26.67%	5.60%	29.51%	2,520.00%
Operating Cash Flow Q/Q Growth	-7.70%	14.38%	-12.79%	-17.02%	13.13%	-31.14%	6.62%	5.05%	13.56%	6.65%	592.03%
Free Cash Flow Firm Q/Q Growth	-193.83%	43.11%	3.07%	-13.58%	-13.38%	127.97%	1,088.45%	-141.00%	24.92%	-61.84%	492,177.68%
Invested Capital Q/Q Growth	67.69%	77.38%	-144.94%	-37.46%	94.77%	-855.62%	-208.71%	-6.60%	-8.14%	0.40%	-0.88%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	97.17%	91.28%	95.47%	100.00%	92.37%	91.30%	95.40%	97.63%	98.65%	97.28%	97.82%
EBITDA Margin	-79.27%	-178.51%	-221.05%	-448.18%	-199.32%	-957.57%	-78.09%	-18.41%	-8.00%	12.17%	40.18%
Operating Margin	-81.74%	-184.45%	-227.95%	-456.20%	-203.66%	-981.12%	-113.08%	-54.81%	-31.29%	-0.56%	38.98%
EBIT Margin	-81.74%	-184.45%	-227.95%	-456.73%	-203.66%	-981.12%	-113.08%	-54.81%	-31.29%	-0.56%	40.36%
Profit (Net Income) Margin	-89.15%	-209.25%	-261.18%	-490.25%	-222.99%	-1,026.35%	-117.11%	-91.25%	-68.36%	-19.72%	30.16%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	101.24%	101.12%	100.14%	102.22%	98.68%
Interest Burden Percent	109.06%	113.45%	114.58%	107.34%	109.49%	104.61%	102.30%	164.64%	218.14%	3,419.35%	75.73%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.32%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-69.75%	-223.70%	-154.16%	-152.26%	-248.94%	-1,925.37%	291.59%	123.07%	60.40%	19.08%	-88.68%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-30.43%	-45.81%	-42.83%	-58.03%	-61.75%	-68.53%	-38.51%	-26.08%	-19.44%	-0.50%	70.29%
Return on Assets (ROA)	-33.19%	-51.97%	-49.07%	-62.29%	-67.61%	-71.69%	-39.89%	-43.42%	-42.46%	-17.65%	52.53%
Return on Common Equity (ROCE)	-69.75%	-223.70%	-154.16%	-152.26%	-248.94%	-1,925.37%	291.59%	123.07%	60.40%	19.08%	-88.68%
Return on Equity Simple (ROE_SIMPLE)	-90.14%	-3,494.55%	-78.53%	-205.65%	-284.68%	949.09%	172.04%	83.88%	49.73%	18.68%	0.00%
Net Operating Profit after Tax (NOPAT)	-28	-34	-40	-66	-70	-122	-124	-104	-73	-1.78	336
NOPAT Margin	-57.22%	-129.11%	-159.56%	-319.34%	-142.56%	-686.78%	-79.15%	-38.37%	-21.91%	-0.40%	38.46%
Net Nonoperating Expense Percent (NNEP)	-21.71%	-63.67%	-54.13%	-47.18%	-80.93%	-70.83%	-23.26%	-48.23%	-102.70%	-152.71%	-40.29%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	165.00%	47.67%	1.11%	-282.40%
Cost of Revenue to Revenue	2.83%	8.72%	4.53%	0.00%	7.63%	8.70%	4.60%	2.37%	1.35%	2.72%	2.18%
SG&A Expenses to Revenue	27.04%	42.70%	55.32%	142.90%	76.01%	381.37%	75.60%	58.85%	64.54%	59.05%	39.85%
R&D to Revenue	150.77%	231.50%	265.87%	411.02%	219.24%	690.34%	132.85%	93.53%	65.35%	38.75%	18.99%
Operating Expenses to Revenue	178.90%	275.73%	323.41%	556.20%	296.03%	1,072.42%	208.48%	152.44%	129.94%	97.84%	58.84%
Earnings before Interest and Taxes (EBIT)	-39	-49	-57	-94	-99	-175	-178	-148	-104	-2.54	353
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-38	-47	-56	-93	-97	-171	-123	-50	-27	55	352
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	15.86	295.87	5.77	17.97	9.96	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	15.86	295.87	5.77	17.97	9.96	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	15.68	17.72	19.18	42.84	7.80	73.85	15.86	7.90	3.70	3.46	1.88
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.24
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.01%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	14.22	17.28	15.04	39.49	6.69	65.27	13.43	7.12	3.44	3.40	1.49
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	27.92	3.72
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.70
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.88
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.76
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	43.43	9.87	0.00	0.00	0.00	4.48
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.63	34.05	0.65	1.20	2.18	-7.77	-1.27	-0.79	-0.67	-0.66	0.00
Long-Term Debt to Equity	0.05	16.15	0.23	0.52	1.17	-6.22	-1.27	-0.79	-0.67	-0.66	0.00
Financial Leverage	-1.15	-1.35	-1.11	-1.13	-1.11	-8.99	4.06	1.48	0.40	0.12	0.61
Leverage Ratio	2.10	4.30	3.14	2.44	3.68	26.86	-7.31	-2.83	-1.42	-1.08	-1.69
Compound Leverage Factor	2.29	4.88	3.60	2.62	4.03	28.09	-7.48	-4.67	-3.10	-36.98	-1.28
Debt to Total Capital	38.74%	97.15%	39.51%	54.54%	68.52%	114.76%	467.70%	-367.81%	-199.11%	-195.49%	0.00%
Short-Term Debt to Total Capital	35.69%	51.07%	25.43%	31.12%	31.75%	22.99%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	3.05%	46.08%	14.08%	23.43%	36.78%	91.77%	467.70%	-367.81%	-199.11%	-195.49%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	61.26%	2.85%	60.49%	45.46%	31.48%	-14.76%	-367.70%	467.81%	299.11%	295.49%	100.00%
Debt to EBITDA	-0.79	-1.14	-0.98	-0.64	-0.86	-0.88	-1.11	-4.65	-11.44	5.74	0.00
Net Debt to EBITDA	1.85	0.24	1.87	0.75	0.56	0.90	3.11	4.26	3.30	-0.48	0.00
Long-Term Debt to EBITDA	-0.06	-0.54	-0.35	-0.27	-0.46	-0.70	-1.11	-4.65	-11.44	5.74	0.00
Debt to NOPAT	-1.09	-1.58	-1.36	-0.90	-1.20	-1.22	-1.09	-2.23	-4.18	-176.88	0.00
Net Debt to NOPAT	2.56	0.34	2.59	1.05	0.78	1.25	3.07	2.04	1.21	14.89	0.00
Long-Term Debt to NOPAT	-0.09	-0.75	-0.49	-0.38	-0.64	-0.98	-1.09	-2.23	-4.18	-176.88	0.00
Altman Z-Score	-0.42	-6.97	-2.48	-3.15	-6.15	-2.94	-0.51	-1.68	-3.01	-2.54	1.91
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.02	1.23	1.68	1.65	1.78	3.06	5.46	4.90	3.31	2.63	2.06
Quick Ratio	0.93	1.17	1.61	1.57	1.72	2.92	5.18	4.50	2.97	2.49	1.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-14	-49	-33	-66	-77	27	214	-86	-36	-42	291
Operating Cash Flow to CapEx	-256.07%	-1,012.66%	-13,019.94%	-25,290.98%	-26,117.78%	-26,285.60%	-5,960.46%	-11,980.01%	-4,388.42%	-4,628.11%	18,111.00%
Free Cash Flow to Firm to Interest Expense	-2.65	-7.62	-3.81	-9.55	-7.68	3.77	61.87	-0.87	-0.26	-0.43	3.03
Operating Cash Flow to Interest Expense	-2.52	-8.24	-4.80	-13.37	-9.00	-19.05	-41.13	-1.63	-0.69	-0.53	3.61
Operating Cash Flow Less CapEx to Interest Expense	-3.51	-9.05	-4.84	-13.42	-9.03	-19.12	-41.82	-1.65	-0.71	-0.54	3.59
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.37	0.25	0.19	0.13	0.30	0.07	0.34	0.48	0.62	0.89	1.74
Accounts Receivable Turnover	6.13	3.51	3.38	3.97	3.69	1.16	8.26	6.77	6.16	6.63	9.41
Inventory Turnover	1.19	2.18	0.00	0.00	0.00	0.00	0.63	0.30	0.16	0.67	2.83
Fixed Asset Turnover	18.02	3.50	2.59	2.21	5.93	2.46	19.86	31.25	40.11	57.46	105.66
Accounts Payable Turnover	0.23	0.34	0.22	0.00	0.34	0.09	0.31	0.30	0.25	0.75	1.39
Days Sales Outstanding (DSO)	59.50	103.95	107.86	91.99	98.80	315.49	44.19	53.92	59.22	55.08	38.78
Days Inventory Outstanding (DIO)	306.17	167.80	0.00	0.00	0.00	0.00	576.36	1,233.87	2,289.54	546.95	129.02
Days Payable Outstanding (DPO)	1,621.69	1,078.63	1,694.92	0.00	1,065.66	3,850.28	1,174.45	1,200.83	1,435.60	483.98	262.82
Cash Conversion Cycle (CCC)	-1,256.02	-806.88	-1,587.06	91.99	-966.86	-3,534.79	-553.90	86.95	913.16	118.04	-95.02
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-16	-0.83	-8.39	-8.23	-1.35	-150	-489	-507	-543	-502	-455
Invested Capital Turnover	-5.19	-3.09	-5.46	-2.48	-10.20	-0.23	-0.49	-0.54	-0.63	-0.86	-1.83
Increase / (Decrease) in Invested Capital	-14	15	-7.56	0.16	6.89	-149	-338	-18	-36	41	45
Enterprise Value (EV)	686	455	379	815	327	1,163	2,110	1,928	1,139	1,531	1,306
Market Capitalization	757	467	483	885	381	1,315	2,492	2,140	1,227	1,558	1,642
Book Value per Share	$0.65	$0.02	$0.85	$0.45	$0.35	($0.11)	($0.59)	($1.58)	($2.22)	($2.30)	($0.57)
Tangible Book Value per Share	$0.65	$0.02	$0.85	$0.45	$0.35	($0.11)	($0.59)	($1.58)	($2.22)	($2.30)	($0.57)
Total Capital	78	55	138	108	122	130	29	-63	-152	-161	-119
Total Debt	30	54	55	59	83	150	136	232	303	315	0.00
Total Long-Term Debt	2.38	25	20	25	45	120	136	232	303	315	0.00
Net Debt	-71	-11	-104	-69	-55	-153	-382	-212	-88	-27	-336
Capital Expenditures (CapEx)	5.12	5.28	0.32	0.37	0.34	0.51	2.39	1.35	2.17	1.12	1.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-24	-15	-32	-27	-27	-54	-49	-15	-45	-59	-67
Debt-free Net Working Capital (DFNWC)	29	41	86	79	111	248	462	411	346	262	208
Net Working Capital (NWC)	1.54	13	51	45	72	218	462	411	346	262	208
Net Nonoperating Expense (NNE)	15	21	26	35	39	60	60	143	154	87	73
Net Nonoperating Obligations (NNO)	-64	-2.41	-92	-57	-40	-131	-382	-212	-88	-27	-336
Total Depreciation and Amortization (D&A)	1.19	1.56	1.74	1.77	2.12	4.19	55	99	77	57	-1.56
Debt-free, Cash-free Net Working Capital to Revenue	-49.39%	-58.16%	-126.69%	-132.84%	-55.67%	-305.64%	-30.88%	-5.46%	-13.52%	-13.20%	-7.62%
Debt-free Net Working Capital to Revenue	60.80%	155.09%	340.57%	380.46%	226.46%	1,393.14%	294.22%	151.75%	104.40%	58.04%	23.81%
Net Working Capital to Revenue	3.19%	47.91%	200.73%	217.28%	147.46%	1,224.71%	294.22%	151.75%	104.40%	58.04%	23.81%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	($0.75)	($0.78)	($0.98)	($0.94)	($1.09)	($1,030.00)	($1.33)	($1.18)	($0.43)	$1.26
Adjusted Weighted Average Basic Shares Outstanding	73.58M	73.96M	98.61M	110.18M	154.19M	177.18M	184.66M	185.91M	192.20M	206.70M	209.89M
Adjusted Diluted Earnings per Share	$0.00	($0.75)	($0.78)	($0.98)	($0.94)	($1.09)	($1,030.00)	($1.33)	($1.18)	($0.43)	$1.21
Adjusted Weighted Average Diluted Shares Outstanding	73.58M	73.70M	84.45M	103.19M	115.60M	167.27M	179.12M	185.91M	192.20M	206.70M	218.58M
Adjusted Basic & Diluted Earnings per Share	($0.59)	($0.75)	($0.78)	($0.98)	($0.94)	($1.09)	($1,030.00)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	73.58M	73.96M	98.61M	110.18M	154.19M	177.18M	184.66M	188.45M	206.15M	208.96M	250.80M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-34	-40	-66	-70	-122	-124	-104	-73	-1.78	336
Normalized NOPAT Margin	-57.22%	-129.11%	-159.56%	-319.34%	-142.56%	-686.78%	-79.15%	-38.37%	-21.91%	-0.40%	38.46%
Pre Tax Income Margin	-89.15%	-209.25%	-261.18%	-490.25%	-222.99%	-1,026.35%	-115.68%	-90.24%	-68.26%	-19.29%	30.56%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-7.59	-7.49	-6.70	-13.62	-9.99	-24.64	-51.42	-1.50	-0.76	-0.03	3.67
NOPAT to Interest Expense	-5.31	-5.25	-4.69	-9.53	-6.99	-17.25	-36.00	-1.05	-0.53	-0.02	3.50
EBIT Less CapEx to Interest Expense	-8.57	-8.31	-6.74	-13.68	-10.02	-24.71	-52.11	-1.51	-0.77	-0.04	3.65
NOPAT Less CapEx to Interest Expense	-6.29	-6.06	-4.73	-9.58	-7.03	-17.32	-36.69	-1.06	-0.54	-0.03	3.48
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from BioCryst Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	250,800,620.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	250,800,620.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-2.88
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	14.39%	17.42%	34.87%	32.54%	34.98%	40.83%	56.89%	49.41%	36.14%	209.09%	7.48%
EBITDA Growth	1,257.40%	-751.35%	122.63%	4,162.10%	148.32%	127.03%	1,548.24%	587.89%	398.38%	4,143.10%	-3,486.98%
EBIT Growth	31.67%	7.86%	49.01%	142.32%	164.52%	89.44%	246.52%	239.98%	319.37%	5,876.06%	-3,412.10%
NOPAT Growth	31.67%	7.86%	49.01%	142.32%	164.52%	89.44%	108.84%	280.78%	484.41%	8,279.26%	-54,904.60%
Net Income Growth	14.98%	13.71%	33.66%	83.17%	61.18%	56.59%	100.09%	140.12%	191.92%	1,017.50%	-2,255,762.50%
EPS Growth	17.39%	18.42%	39.29%	85.00%	63.16%	58.06%	100.00%	133.33%	185.71%	969.23%	0.00%
Operating Cash Flow Growth	38.67%	62.61%	-12.99%	92.73%	141.44%	41.55%	48.74%	3,119.15%	404.84%	5,700.61%	-124.56%
Free Cash Flow Firm Growth	-93.97%	144.77%	37.26%	-93.33%	-58.32%	-785.70%	-1,927.87%	-3,474.41%	-383.55%	563.95%	-852.51%
Invested Capital Growth	-5.62%	-7.15%	-2.67%	1.09%	-0.45%	7.48%	11.05%	8.94%	10.55%	9.01%	7.29%
Revenue Q/Q Growth	5.15%	7.68%	-0.69%	17.86%	7.09%	12.34%	10.64%	12.24%	-2.42%	155.06%	-61.53%
EBITDA Q/Q Growth	1,296.45%	-417.21%	107.93%	1,112.76%	-18.64%	-65.47%	383.74%	-53.53%	102.83%	704.74%	-370.23%
EBIT Q/Q Growth	42.42%	-257.94%	66.05%	160.47%	-12.20%	-158.61%	570.90%	40.31%	8.30%	707.20%	-370.01%
NOPAT Q/Q Growth	42.42%	-257.94%	66.05%	160.47%	-12.20%	-158.61%	128.40%	2,505.89%	34.75%	720.24%	-290.28%
Net Income Q/Q Growth	52.01%	-70.77%	42.69%	64.18%	-10.72%	-90.94%	100.12%	15,790.63%	153.67%	1,805.92%	-393.60%
EPS Q/Q Growth	52.50%	-63.16%	45.16%	64.71%	-16.67%	-85.71%	100.00%	0.00%	200.00%	1,783.33%	-363.72%
Operating Cash Flow Q/Q Growth	-5.76%	55.18%	-501.97%	97.45%	702.70%	-163.23%	-427.85%	250.10%	0.78%	601.42%	-121.16%
Free Cash Flow Firm Q/Q Growth	94.01%	-65.28%	-15.04%	-78.98%	1,111.85%	-671.19%	-25.60%	61.19%	-1.83%	1,079.92%	-345.93%
Invested Capital Q/Q Growth	0.64%	-8.14%	6.33%	1.21%	-0.91%	0.40%	10.41%	-1.13%	0.87%	-0.88%	8.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.73%	98.33%	98.64%	98.45%	97.26%	95.37%	96.86%	98.29%	98.63%	97.66%	96.56%
EBITDA Margin	9.51%	-28.03%	2.24%	23.04%	17.50%	5.38%	23.52%	9.74%	20.25%	63.88%	-448.65%
Operating Margin	-13.74%	-45.68%	-15.62%	8.01%	6.57%	-3.43%	14.59%	18.23%	18.56%	64.05%	-448.55%
EBIT Margin	-13.74%	-45.68%	-15.62%	8.01%	6.57%	-3.43%	14.59%	18.23%	20.24%	64.05%	-449.49%
Profit (Net Income) Margin	-41.67%	-66.09%	-38.14%	-11.59%	-11.99%	-20.37%	0.02%	3.11%	8.09%	60.47%	-461.48%
Tax Burden Percent	100.92%	97.73%	101.04%	101.38%	104.36%	103.09%	4.22%	78.40%	106.34%	99.12%	100.14%
Interest Burden Percent	300.47%	148.02%	241.68%	-142.70%	-174.82%	576.55%	3.57%	21.78%	37.60%	95.25%	102.52%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	95.78%	21.60%	-6.34%	0.88%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	72.32%	60.40%	51.86%	33.77%	28.15%	19.08%	11.52%	7.96%	2.05%	-88.68%	91.07%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-8.07%	-28.38%	-11.36%	6.11%	5.35%	-3.07%	15.49%	21.87%	25.89%	111.55%	-842.49%
Return on Assets (ROA)	-24.47%	-41.06%	-27.73%	-8.84%	-9.75%	-18.23%	0.02%	3.73%	10.35%	105.32%	-864.96%
Return on Common Equity (ROCE)	72.32%	60.40%	51.86%	33.77%	28.15%	19.08%	11.52%	7.96%	2.05%	-88.68%	91.07%
Return on Equity Simple (ROE_SIMPLE)	57.51%	0.00%	43.81%	30.68%	26.42%	0.00%	11.83%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-8.34	-30	-10	6.13	5.38	-3.16	0.90	23	31	258	-491
NOPAT Margin	-9.62%	-31.98%	-10.93%	5.61%	4.60%	-2.40%	0.62%	14.30%	19.74%	63.49%	-313.99%
Net Nonoperating Expense Percent (NNEP)	-17.16%	-21.26%	-25.96%	-26.67%	-30.55%	-41.45%	-6.16%	-63.05%	-37.40%	-6.80%	333.51%
Return On Investment Capital (ROIC_SIMPLE)	-	19.61%	-	-	-	1.96%	-0.67%	-13.21%	-16.41%	-216.62%	311.87%
Cost of Revenue to Revenue	1.27%	1.67%	1.36%	1.55%	2.74%	4.63%	3.14%	1.71%	1.37%	2.34%	3.44%
SG&A Expenses to Revenue	58.39%	68.93%	64.00%	55.99%	55.59%	61.18%	56.67%	53.49%	52.08%	23.56%	60.45%
R&D to Revenue	54.04%	75.00%	50.12%	34.41%	35.09%	37.59%	25.61%	26.56%	27.98%	10.05%	484.67%
Operating Expenses to Revenue	112.48%	144.02%	114.25%	90.43%	90.69%	98.79%	82.28%	80.05%	80.06%	33.61%	545.12%
Earnings before Interest and Taxes (EBIT)	-12	-43	-14	8.76	7.69	-4.51	21	30	32	260	-703
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	8.25	-26	2.08	25	20	7.08	34	16	32	260	-702
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	4.22	3.70	2.93	3.34	3.81	3.46	3.11	3.36	2.66	1.88	2.70
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.24	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	16.01%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	3.94	3.44	2.84	3.27	3.72	3.40	3.12	3.32	2.56	1.49	2.85
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	133.95	71.19	27.92	18.04	17.42	11.88	3.72	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	47.30	34.12	20.19	3.70	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	67.57	48.74	28.84	3.88	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	109.95	30.61	3.76	8.06
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25,950.73	4.48	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-0.75	-0.67	-0.65	-0.66	-0.67	-0.66	-0.70	-0.58	-0.51	0.00	-0.72
Long-Term Debt to Equity	-0.75	-0.67	-0.65	-0.66	-0.67	-0.66	-0.70	-0.58	-0.51	0.00	-0.72
Financial Leverage	0.50	0.40	0.24	0.16	0.14	0.12	0.03	0.06	0.12	0.61	-0.14
Leverage Ratio	-1.65	-1.42	-1.22	-1.16	-1.15	-1.08	-1.02	-1.04	-1.09	-1.69	-0.94
Compound Leverage Factor	-4.97	-2.11	-2.94	1.65	2.02	-6.24	-0.04	-0.23	-0.41	-1.61	-0.96
Debt to Total Capital	-298.92%	-199.11%	-183.97%	-193.98%	-203.81%	-195.49%	-236.76%	-138.52%	-102.26%	0.00%	-251.71%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	-298.92%	-199.11%	-183.97%	-193.98%	-203.81%	-195.49%	-236.76%	-138.52%	-102.26%	0.00%	-251.71%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	398.92%	299.11%	283.97%	293.98%	303.81%	295.49%	336.76%	238.52%	202.26%	100.00%	351.71%
Debt to EBITDA	-90.31	-11.44	-20.22	33.60	14.57	5.74	3.65	2.31	1.52	0.00	-1.07
Net Debt to EBITDA	26.75	3.30	1.96	-2.60	-1.66	-0.48	0.02	-0.24	-0.44	0.00	-0.37
Long-Term Debt to EBITDA	-90.31	-11.44	-20.22	33.60	14.57	5.74	3.65	2.31	1.52	0.00	-1.07
Debt to NOPAT	-4.10	-4.18	-4.91	-7.43	-11.03	-176.88	13.68	6.45	3.68	0.00	-1.48
Net Debt to NOPAT	1.21	1.21	0.48	0.58	1.26	14.89	0.08	-0.68	-1.07	0.00	-0.51
Long-Term Debt to NOPAT	-4.10	-4.18	-4.91	-7.43	-11.03	-176.88	13.68	6.45	3.68	0.00	-1.48
Altman Z-Score	-2.00	-2.62	-2.98	-2.85	-2.43	-2.56	-2.28	-2.11	-2.32	1.31	-7.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.54	3.31	3.73	2.82	2.78	2.63	2.93	2.25	1.87	2.06	1.91
Quick Ratio	4.97	2.97	3.31	2.64	2.62	2.49	2.78	1.98	1.60	1.95	1.78
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	18	6.39	3.01	0.63	7.67	-44	-55	-21	-22	213	-524
Operating Cash Flow to CapEx	-2,015.91%	-1,609.75%	-22,844.26%	-882.58%	13,974.58%	-772.30%	-19,242.66%	23,073.74%	3,097.02%	36,403.99%	-15,332.75%
Free Cash Flow to Firm to Interest Expense	0.67	0.26	0.12	0.03	0.31	-1.79	-2.34	-0.83	-0.97	8.68	-26.49
Operating Cash Flow to Interest Expense	-0.73	-0.36	-2.19	-0.06	0.33	-0.21	-1.17	1.60	1.86	11.89	-3.12
Operating Cash Flow Less CapEx to Interest Expense	-0.76	-0.39	-2.20	-0.06	0.33	-0.24	-1.18	1.60	1.80	11.86	-3.14
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.59	0.62	0.73	0.76	0.81	0.89	1.06	1.20	1.28	1.74	1.87
Accounts Receivable Turnover	6.60	6.16	6.51	6.05	6.54	6.63	6.54	6.97	7.32	9.41	8.74
Inventory Turnover	0.19	0.16	0.17	0.36	0.42	0.67	0.85	3.51	2.45	2.83	3.09
Fixed Asset Turnover	36.37	40.11	43.86	47.48	50.25	57.46	65.29	69.17	75.84	105.66	104.44
Accounts Payable Turnover	0.55	0.25	0.53	0.52	0.64	0.75	1.42	2.04	1.64	1.39	1.89
Days Sales Outstanding (DSO)	55.32	59.22	56.09	60.36	55.78	55.08	55.81	52.36	49.83	38.78	41.76
Days Inventory Outstanding (DIO)	1,948.08	2,289.54	2,169.80	1,022.36	877.85	546.95	429.58	103.93	149.22	129.02	118.01
Days Payable Outstanding (DPO)	659.88	1,435.60	688.46	703.86	567.63	483.98	257.35	179.26	222.18	262.82	192.81
Cash Conversion Cycle (CCC)	1,343.51	913.16	1,537.43	378.86	366.00	118.04	228.04	-22.97	-23.12	-95.02	-33.03
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-502	-543	-506	-500	-504	-502	-450	-455	-451	-455	-417
Invested Capital Turnover	-0.65	-0.63	-0.71	-0.76	-0.82	-0.86	-1.05	-1.17	-1.26	-1.83	-2.04
Increase / (Decrease) in Invested Capital	-27	-36	-13	5.50	-2.28	41	56	45	53	45	33
Enterprise Value (EV)	1,250	1,139	1,011	1,251	1,536	1,531	1,569	1,849	1,536	1,306	2,524
Market Capitalization	1,342	1,227	1,040	1,275	1,572	1,558	1,567	1,875	1,593	1,642	2,388
Book Value per Share	($2.17)	($2.22)	($2.31)	($2.30)	($2.26)	($2.30)	($2.16)	($2.01)	($1.85)	($0.57)	($2.21)
Tangible Book Value per Share	($2.17)	($2.22)	($2.31)	($2.30)	($2.26)	($2.30)	($2.16)	($2.01)	($1.85)	($0.57)	($2.21)
Total Capital	-103	-152	-168	-162	-154	-161	-134	-177	-192	-119	-157
Total Debt	308	303	308	314	314	315	318	245	196	0.00	396
Total Long-Term Debt	308	303	308	314	314	315	318	245	196	0.00	396
Net Debt	-91	-88	-30	-24	-36	-27	1.80	-26	-57	-336	137
Capital Expenditures (CapEx)	0.99	0.55	0.24	0.16	0.06	0.68	0.14	0.18	1.34	0.80	0.40
Debt-free, Cash-free Net Working Capital (DFCFNWC)	13	-45	-11	-39	-57	-59	-25	-39	-48	-67	-61
Debt-free Net Working Capital (DFNWC)	412	346	327	234	274	262	270	221	165	208	178
Net Working Capital (NWC)	412	346	327	234	274	262	270	221	165	208	178
Net Nonoperating Expense (NNE)	28	32	25	19	19	24	0.86	18	19	12	231
Net Nonoperating Obligations (NNO)	-91	-88	-30	-24	-36	-27	1.80	-34	-63	-336	137
Total Depreciation and Amortization (D&A)	20	16	17	16	13	12	13	-14	0.01	-0.70	1.31
Debt-free, Cash-free Net Working Capital to Revenue	3.95%	-13.52%	-3.14%	-10.32%	-13.88%	-13.20%	-5.02%	-7.04%	-8.00%	-7.62%	-6.89%
Debt-free Net Working Capital to Revenue	129.65%	104.40%	92.06%	61.32%	66.30%	58.04%	53.65%	39.70%	27.58%	23.81%	20.12%
Net Working Capital to Revenue	129.65%	104.40%	92.06%	61.32%	66.30%	58.04%	53.65%	39.70%	27.58%	23.81%	20.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)	$0.00	$0.02	$0.06	$1.18	($2.98)
Adjusted Weighted Average Basic Shares Outstanding	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M	208.88M	209.52M	210.18M	209.89M	242.26M
Adjusted Diluted Earnings per Share	($0.19)	($0.31)	($0.17)	($0.06)	($0.07)	($0.13)	$0.00	$0.02	$0.06	$1.13	($2.98)
Adjusted Weighted Average Diluted Shares Outstanding	189.64M	192.20M	206.06M	206.43M	206.91M	206.70M	215.26M	219.89M	219.89M	218.58M	242.26M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	204.81M	206.15M	206.38M	206.89M	207.13M	208.96M	209.25M	209.92M	210.54M	250.80M	254.16M
Normalized Net Operating Profit after Tax (NOPAT)	-8.34	-30	-10	6.13	5.38	-3.16	15	23	21	258	-491
Normalized NOPAT Margin	-9.62%	-31.98%	-10.93%	5.61%	4.60%	-2.40%	10.21%	14.30%	13.00%	63.49%	-313.99%
Pre Tax Income Margin	-41.29%	-67.62%	-37.75%	-11.43%	-11.48%	-19.76%	0.52%	3.97%	7.61%	61.00%	-460.84%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-0.44	-1.74	-0.59	0.35	0.31	-0.18	0.90	1.16	1.44	10.60	-35.55
NOPAT to Interest Expense	-0.31	-1.22	-0.41	0.25	0.22	-0.13	0.04	0.91	1.40	10.51	-24.83
EBIT Less CapEx to Interest Expense	-0.47	-1.76	-0.60	0.35	0.31	-0.21	0.90	1.15	1.38	10.57	-35.57
NOPAT Less CapEx to Interest Expense	-0.34	-1.24	-0.42	0.24	0.21	-0.16	0.03	0.90	1.34	10.48	-24.85
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

BioCryst Pharmaceuticals (BCRX) has shown notable volatility and a dramatic quarterly shift in profitability in the latest four years of quarterly statements. Below are the top trends and takeaways for retail investors, focusing on the most important, observable data points across income statements, cash flows, and balance sheets.

Massive Q4 2025 revenue and gross margin: Operating revenue of 406,555,000 and total gross profit of 397,033,000 imply an extremely high gross margin (about 97.7%), driven by a large quarterly topline with minimal cost of revenue (9,522,000).
Strong Q4 2025 earnings per share and net income: Net income attributable to common shareholders of 244,954,000 and Basic/Diluted EPS of 1.18/1.13 reflect a rare, substantial quarterly profitability for BioCryst.
Solid Q4 2025 operating income and cost control: Total operating income of 260,385,000 against operating expenses of 136,648,000 indicates a healthy operating margin in the quarter (SG&A 95,781,000 and R&D 40,867,000).
Robust cash generation from operations in Q4 2025: Net cash from continuing operating activities reached 291,960,000, signaling strong cash generation to fund investing/financing activities.
Revenue growth trend across 2024–2025: Revenue rose meaningfully from about 131.5 million in Q4 2024 to roughly 406.6 million in Q4 2025, marking a substantial year-over-year acceleration.
Balance sheet leverage and solvency risk: Across 2025, total liabilities (~834–959 million) exceeded total assets (~446–480 million), resulting in negative equity (e.g., about -387.9 million to -468.6 million). This indicates significant leverage and solvency concerns relative to asset base.
Deleveraging trend within 2025: Long-term debt declined through 2025 (approx. 315.4 million in Q1 2025 to about 194.4 million by Q3 2025), suggesting the company is reducing leverage over the year.
Heavy financing outflows observed in 2025: Net cash from financing activities remained negative in several quarters, with Q4 2025 showing a large outflow (~-217.96 million), reflecting ongoing external funding needs.
Ongoing restatements and data comparability concerns: Earlier quarters have restatements (e.g., restated Q2/Q3 2023 and other periods), which can complicate year-over-year comparisons and valuation judgments.
Persistent equity decline and high liability burden: The combination of negative equity and elevated liabilities relative to assets signals persistent capital-structure headwinds that investors should monitor for sustainability of profitability and financing flexibility.

05/25/26 09:53 PM ETAI Generated. May Contain Errors.

BioCryst Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioCryst Pharmaceuticals' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BioCryst Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $263.86 million in 2025, falling from -$43.02 million in 2015. The previous period was -$88.88 million in 2024. See where experts think BioCryst Pharmaceuticals is headed by visiting BioCryst Pharmaceuticals' forecast page.

BioCryst Pharmaceuticals' total operating income in 2025 was $340.99 million, based on the following breakdown:

Total Gross Profit: $855.76 million
Total Operating Expenses: $514.77 million

Over the last 10 years, BioCryst Pharmaceuticals' total revenue changed from $48.26 million in 2015 to $874.84 million in 2025, a change of 1,712.9%.

BioCryst Pharmaceuticals' total liabilities were at $633.31 million at the end of 2025, a 34.5% decrease from 2024, and a 748.5% increase since 2015.

In the past 10 years, BioCryst Pharmaceuticals' cash and equivalents has ranged from $22.10 million in 2016 to $504.39 million in 2021, and is currently $89.74 million as of their latest financial filing in 2025.

Over the last 10 years, BioCryst Pharmaceuticals' book value per share changed from 0.65 in 2015 to -0.57 in 2025, a change of -187.0%.

Related Companies

Financial statements for NASDAQ:BCRX last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioCryst Pharmaceuticals (BCRX) Financials

Financials Breakdown Chart

Key Financial Trends

BioCryst Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioCryst Pharmaceuticals (BCRX) Financials

Annual Income Statements for BioCryst Pharmaceuticals

Quarterly Income Statements for BioCryst Pharmaceuticals

Annual Cash Flow Statements for BioCryst Pharmaceuticals

Quarterly Cash Flow Statements for BioCryst Pharmaceuticals

Annual Balance Sheets for BioCryst Pharmaceuticals

Quarterly Balance Sheets for BioCryst Pharmaceuticals

Annual Metrics And Ratios for BioCryst Pharmaceuticals

Quarterly Metrics And Ratios for BioCryst Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

BioCryst Pharmaceuticals Financials - Frequently Asked Questions

When does BioCryst Pharmaceuticals' financial year end?

How has BioCryst Pharmaceuticals' net income changed over the last 10 years?

What is BioCryst Pharmaceuticals' operating income?

How has BioCryst Pharmaceuticals' revenue changed over the last 10 years?

How much debt does BioCryst Pharmaceuticals have?

How much cash does BioCryst Pharmaceuticals have?

How has BioCryst Pharmaceuticals' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools